1. Pink Sheet
  2. >>Geography
  3. >>Europe

Brexit: How Do Pharma Firms Plan For An Unknown Scenario?

 
• By Vibha Sharma

As the Brexit negotiations continue, the pharmaceutical industry is anxious to have a cut-off date when it should start taking action to deal with the legal repercussions of the UK becoming a third country within the context of the EU medicines network. There are no clear answers yet, and companies are being asked to continue to wait and watch.

Indecision
Brexit Continues To Pose Uncertainty For Drug Companies • Source: Shutterstock

There is a high degree of anxiety among drug companies with some or all of their operations in the UK as to when – and if at all – they should start implementing the EU medicines network’s recent guidance on Brexit.

The only advice being handed out to them right now is to continue to wait and watch for more details...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Europe

New EU Filings

 
• By Neena Brizmohun

Arimoclomol, Zevra Therapeutics's treatment for Niemann-Pick disease Type C, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.

Sanofi Secures EU Fast-Track Status For ‘Game-Changing’ Sleeping Sickness Drug

 
• By Neena Brizmohun

If approved, Sanofi’s acoziborole could become the first single-dose oral treatment for sleeping sickness.

UK Approves Biogen’s Qalsody After England Revises Reimbursement Approach

 
• By Eliza Slawther

Biogen has U-turned on its original decision not to file Qalsody for marketing approval in the UK for treating certain patients with amyotrophic lateral sclerosis. The move appears to have been triggered by a change in the reimbursement pathway agreed for the product.

New CTIS Feature To Bridge ‘Communication Gap’ Between Trial Sponsors & EU Assessors

 
• By Vibha Sharma

A task force set up by the EMA to identify and prioritize improvements to the Clinical Trials Information System has recommended several measures to enhance CTIS’ usability and efficiency, including the potential introduction of a communication tool for direct sponsor-assessor interaction.

More from Geography